Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have never really managed to recreate the success they had in 2020 amid the Covid-19 outbreak. For a second year in running, the sector is caught in a rut, underperforming the beaten-down broader market. Th...
Kezar Life Sciences press release (NASDAQ:KZR): Q1 GAAP EPS of -$0.26 beats by $0.02. Cash, cash equivalents and marketable securities totaled $242.6 million as of March 31, 2022 For further details see: Kezar Life Sciences GAAP EPS of -$0.26 beats by $0.02
Topline data from MISSION Phase 2 trial of zetomipzomib for the treatment of lupus nephritis expected in June 2022, consistent with previous guidance KZR-261 continues to enroll patients with solid tumors in Phase 1 dose-escalation trial Company to host virtual Inves...
Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted t...
ArcelorMittal S.A. (NYSE:MT) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is $3.41 (+76.7% Y/Y) and the consensus Revenue Estimate is $20.83B (+28.7% Y/Y). Over the last 1 year, MT has beaten EPS estimates 75% of the time an...
Gainers: Sharps Technology (STSS) +43%. TransMedics Group (TMDX) +30%. Super Micro Computer (SMCI) +25%. CarParts.com (PRTS) +25%. Superior Industries International (SUP) +22%. Livent (LTHM) +23%. Bright Health Group (BHG) +21%. eHealth (EHTH) +19%. BlueLinx Holdings (BXC) +18%. Kimball Inter...
Gainers: Bright Health Group BHG +21%. TransMedics Group TMDX +21%. Belite Bio (BLTE) +11%. Sharps Technology STSS +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma CNTB -45%. Amarin AMRN -43%. Kezar Life Sciences (KZR) -35%. MacroGenic...
Announcing topline data from its PRESIDIO Phase 2 trial, the clinical-stage biotech Kezar Life Sciences (NASDAQ:KZR) said on Tuesday that its lead asset, zetomipzomib failed to show a significant differentiation from placebo in patients with dermatomyositis (DM) and polymyositis (PM). Kezar (...
Most patients saw clinically meaningful improvements in the primary endpoint measure of Total Improvement Score (TIS), but no differentiation from placebo was observed Zetomipzomib demonstrates a favorable safety and tolerability profile, including in the PRESIDIO Open-l...
Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the company’s Board of Directors has granted one employee a nonqualified...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...